中文
| Catalogue |
| Recommend Products |
Company News
- AMSBIO ScreenIn3D Innovation Draws Accolades 10/8/2018
- AMSBIO: Circulating Tumor DNA Reference Standards 9/19/2018
- AMSBIO: Engineering Immune Cells to Treat Cancers 8/24/2018
- AMSBIO: Flexible & Precise Control of Gene Expression 8/17/2018
- AMSBIO: Exosome Isolation Manufacturing & Characterization 7/24/2018
- AMSBIO: Powerful CRISPR/Cas9 Gene Editing Kits 7/19/2018
- AMSBIO Launch New Screening Company 7/5/2018
- AMSBIO: 3D-iPSC Matrix Enables More Accurate In Vivo Predictions 6/21/2018
- AMSBIO: Cell Culture Medium for Clinical Research 6/5/2018
- AMSBIO: High Throughput Gene Expression Analysis Service 5/15/2018
- AMSBIO: Isogenic Cell Lines for Cancer Research 5/3/2018
- AMSBIO: Sustained Episomal Gene Expression Free from Foreign DNA 4/18/2018
- AMSBIO : Comprehensive Toolkit for Exosome Research 3/29/2018
- AMSBIO Signs Global Agreement for Groundbreaking Myotube Technology 3/23/2018
- AMSBIO: Immunotherapy Used to Treat Aggressive Colon Tumors 3/5/2018
- AMSBIO: High Throughput PARP Screening Assay 2/22/2018
- AMSBIO : Novel Microfluidic Platform for Cancer Research 2/5/2018
- AMSBI: Isogenic Panels of Neuronal iPSC Derivatives 1/19/2018
- AMSBIO : Highest Stability Recombinant Wnt3a for Organoid Culture 1/3/2018
- AMSBIO: Highly Efficient Substrate for Culturing ES/iPS Cells 12/18/2017